scholarly journals IL4/IL4R signaling promotes the osteolysis in metastatic bone of CRC through regulating the proliferation of osteoclast precursors

2021 ◽  
Vol 27 (1) ◽  
Author(s):  
Qian Jin ◽  
He Yang ◽  
Zhao Jing ◽  
Wu Hong-hua ◽  
Song Ben-jing ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Bone Metastasis ◽  
Bone Destruction ◽  
Type I ◽  
Erk Pathway ◽  
Osteolytic Lesions ◽  
Osteoclast Precursors ◽  
Metastatic Microenvironment ◽  
Metastatic Sites

Abstract Background Bone metastasis of colorectal cancer (CRC) often indicates a poor prognosis. Osteolysis can be observed in metastatic sites, implying an aberrant activation of osteoclasts. However, how osteoclastogenesis is regulated in metastatic microenvironment caused by colorectal cancer is still unclear. Methods In this study, mice bone metastatic model of CRC was established through injection of MC-38 or CT-26 cells. BrdU assays showed primary CD115 ( +) osteoclast precursors (OCPs) proliferated at the first 2 weeks. Transcriptomic profiling was performed to identify differentially expressing genes and pathways in OCPs indirectly co-cultured with CRC cells Results The expression of IL4Rα was found to be significantly upregulated in OCPs stimulated by tumor conditioned medium (CM). Further investigation indicated that IL-4 signaling regulated proliferation of OPCs through interacting with type I IL4 receptor, and neutrophils were the main source of IL-4 in bone marrow. The proliferation of OCPs can be inhibited in IL4 deficiency mice. In addition, ERK pathway was activated by IL4/IL4R signaling. Ravoxertinib, an ERK antagonists, could significantly prevent bone destruction through inhibiting the proliferation of OCPs. Conclusion Our study indicates the essential role of IL4/IL4R signaling for the proliferation of OCPs in early metastasis of CRC predominantly through activating ERK pathway, which remarkedly impacts the number of osteoclasts in later stage and leads to osteolytic lesions. Moreover, Ravoxertinib could be a new therapeutical target for bone metastasis of CRC.

scholarly journals IL-17A gene transfer induces bone loss and epidermal hyperplasia associated with psoriatic arthritis

2014 ◽  
Vol 74 (6) ◽  
pp. 1284-1292 ◽  
Author(s):  
Iannis E Adamopoulos ◽  
Erika Suzuki ◽  
Cheng-Chi Chao ◽  
Dan Gorman ◽  
Sarvesh Adda ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Gene Transfer ◽  
Bone Resorption ◽  
Bone Loss ◽  
Bone Destruction ◽  
Chronic Inflammatory Disease ◽  
Epidermal Hyperplasia ◽  
Osteoclast Precursors

BackgroundPsoriatic arthritis (PsA) is a chronic inflammatory disease characterised by clinical features that include bone loss and epidermal hyperplasia. Aberrant cytokine expression has been linked to joint and skin pathology; however, it is unclear which cytokines are critical for disease initiation. Interleukin 17A (IL-17A) participates in many pathological immune responses; however, its role in PsA has not been fully elucidated.ObjectiveTo determine the role of IL-17A in epidermal hyperplasia and bone destruction associated with psoriatic arthritis.DesignAn in vivo gene transfer approach was used to investigate the role of IL-17A in animal models of inflammatory (collagen-induced arthritis) and non-inflammatory (receptor activator of NF-κB ligand (RANKL)-gene transfer) bone loss.ResultsIL-17A gene transfer induced the expansion of IL-17RA+CD11b+Gr1low osteoclast precursors and a concomitant elevation of biomarkers indicative of bone resorption. This occurred at a time preceding noticeable joint inflammation, suggesting that IL-17A is critical for the induction of pathological bone resorption through direct activation of osteoclast precursors. Moreover, IL-17A induced a second myeloid population CD11b+Gr1high neutrophil-like cells, which was associated with cutaneous pathology including epidermal hyperplasia, parakeratosis and Munro's microabscesses formation.ConclusionsCollectively, these data support that IL-17A can play a key role in the pathogenesis of inflammation-associated arthritis and/or skin disease, as observed in PsA.

Rituximab abrogates joint destruction in rheumatoid arthritis by inhibiting osteoclastogenesis

2011 ◽  
Vol 71 (1) ◽  
pp. 108-113 ◽  
Author(s):  
Maria J H Boumans ◽  
Rogier M Thurlings ◽  
Lorraine Yeo ◽  
Dagmar Scheel-Toellner ◽  
Koen Vos ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Joint Destruction ◽  
Bone Destruction ◽  
Nuclear Factor Κb ◽  
Type I ◽  
Nuclear Factor ◽  
Rankl Expression ◽  
Osteoclast Precursors ◽  
Receptor Activator ◽  
Hands And Feet

ObjectivesTo examine how rituximab may result in the inhibition of joint destruction in rheumatoid arthritis (RA) patients.MethodsTwenty-eight patients with active RA were treated with rituximab. Radiographs of hands and feet before and 1 year after therapy were assessed using the Sharp–van der Heijde score (SHS). Expression of bone destruction markers was evaluated by immunohistochemistry and immunofluorescence of synovial biopsies obtained before and 16 weeks after the initiation of treatment. Serum levels of osteoprotegerin, receptor activator of nuclear factor κB ligand (RANKL), osteocalcin and cross-linked N-telopeptides of type I collagen (NTx) were measured by ELISA before and 16 weeks post-treatment.ResultsAfter 1 year, the mean (SD) change in total SHS was 1.4 (10.0). Sixteen weeks after treatment there was a decrease of 99% in receptor activator of nuclear factor κB-positive osteoclast precursors (p=0.02) and a decrease of 37% (p=0.016) in RANKL expression in the synovium and a trend towards reduced synovial osteoprotegerin expression (25%, p=0.07). In serum, both osteoprotegerin (20%, p=0.001) and RANKL (40%, p<0.0001) levels were significantly reduced 16 weeks after treatment, but the osteoprotegerin/RANKL ratio increased (157%, p=0.006). A trend was found towards an increase of osteocalcin levels (p=0.053), while NTx concentrations did not change.ConclusionsRituximab treatment is associated with a decrease in synovial osteoclast precursors and RANKL expression and an increase in the osteoprotegerin/RANKL ratio in serum. These observations may partly explain the protective effect of rituximab on the progression of joint destruction in RA.

scholarly journals Role of Type I and II Interferons in Colorectal Cancer and Melanoma

2017 ◽  
Vol 8 ◽  
Author(s):  
Simone Di Franco ◽  
Alice Turdo ◽  
Matilde Todaro ◽  
Giorgio Stassi
Keyword(s):  
Colorectal Cancer ◽  
Type I

scholarly journals T-614 Promotes Osteoblastic Cell Differentiation by Increasing Dlx5 Expression and Regulating the Activation of p38 and NF-κB

2018 ◽  
Vol 2018 ◽  
pp. 1-8 ◽  
Author(s):  
Jinglue Song ◽  
Hongli Liu ◽  
Qi Zhu ◽  
Yutong Miao ◽  
Feiyan Wang ◽  
...  
Keyword(s):  
Ectopic Expression ◽  
Bone Destruction ◽  
Collagen Type I ◽  
Inhibitory Effect ◽  
Osteoblastic Differentiation ◽  
Nodule Formation ◽  
Osteoblastic Cell ◽  
Type I ◽  
Autoimmune Inflammatory Disease

Rheumatoid arthritis (RA) is an autoimmune inflammatory disease characterized by bone loss. Degree of inflammation has been identified as an important initiator of skeletal damage in RA. Iguratimod (T-614) is an anti-inflammatory agent which has been reported to show the inhibitory effect of bone destruction in RA. However, the role of T-614 in osteoblast differentiation is still not clear. In this study, we intended to find the effect of T-614 on the osteogenesis process. We detected osteogenesis markers and transcription factors associated with osteoblastic lineage and bone formation in the culture of mesenchymal stem cells which differentiate osteoblast. The contents and activity of alkaline phosphatase, levels of collagen type I and bone gla protein, and calcium nodule formation were increased significantly after T-614 treated. Meanwhile, the mRNAs expressions of Osterix and Dlx5 were also found to be increased significantly by real-time PCR. The changes of levels of phosphorylation of p38 and NF-κB were also detected by Western blot. The results showed that T-614 promotes osteoblastic differentiation by increasing the expression of Osterix and Dlx5 and increasing the activation of P38. T-614 could advance the ectopic expression of NF-κB to suppress inflammation, which indirectly inhibits the damage of the osteoblasts.

scholarly journals Bornlisy Attenuates Colitis-Associated Colorectal Cancer via Inhibiting GPR43-Mediated Glycolysis

2021 ◽  
Vol 8 ◽  
Author(s):  
Xia Lu ◽  
Shuping Qiao ◽  
Chen Peng ◽  
Wenyue Yan ◽  
Zhen Xu ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Colon Cancer ◽  
Antitumor Effect ◽  
Intervention Strategy ◽  
Underlying Mechanism ◽  
Protective Role ◽  
Erk Pathway ◽  
Proliferation And Metastasis

There is evidence that probiotics have a broad antitumor effect in colorectal cancer (CRC). However, the mechanism remains obscure. Here, we investigated the effect of Bornlisy (BO)-cocktails of three probiotics on colitis-associated colon cancer (CAC) and the underlying mechanism. The treatment of CAC mice with BO resulted in decreased tumor loads as compared with their counterparts. BO also inhibited the proliferation and metastasis of CRC cells in vitro. Furthermore, BO inhibited cell proliferation through downregulating glycolysis. Activating glycolysis reversed the protective role of BO in the CAC mice. Mechanically, BO administration promoted the activation of GPR43, followed by its downstream PLC-PKC-ERK pathway, which led to decreased glucose metabolism. These results suggest that BO may provide an intervention strategy for CRC therapy, while GPR43 is a potential targeting receptor during the BO treatment.

scholarly journals Conventional NK cells and tissue-resident ILC1s join forces to control liver metastasis

2021 ◽  
Vol 118 (27) ◽  
pp. e2026271118
Author(s):  
Laura Ducimetière ◽  
Giulia Lucchiari ◽  
Gioana Litscher ◽  
Marc Nater ◽  
Laura Heeb ◽  
...  
Keyword(s):  
Liver Metastasis ◽  
Hepatic Metastases ◽  
Lymphocyte Subpopulations ◽  
Lymphoid Cells ◽  
Type I ◽  
Cancer Type ◽  
Preclinical Models ◽  
Metastatic Microenvironment ◽  
And Function

The liver is a major metastatic target organ, and little is known about the role of immunity in controlling hepatic metastases. Here, we discovered that the concerted and nonredundant action of two innate lymphocyte subpopulations, conventional natural killer cells (cNKs) and tissue-resident type I innate lymphoid cells (trILC1s), is essential for antimetastatic defense. Using different preclinical models for liver metastasis, we found that trILC1 controls metastatic seeding, whereas cNKs restrain outgrowth. Whereas the killing capacity of trILC1s was not affected by the metastatic microenvironment, the phenotype and function of cNK cells were affected in a cancer type–specific fashion. Thus, individual cancer cell lines orchestrate the emergence of unique cNK subsets, which respond differently to tumor-derived factors. Our findings will contribute to the development of therapies for liver metastasis involving hepatic innate cells.

The dramatic role of IFN family in aberrant inflammatory osteolysis

2020 ◽  
Vol 20 ◽  
Author(s):  
Zihan Deng ◽  
Wenhui Hu ◽  
Hongbo Ai ◽  
Yueqi Chen ◽  
Shiwu Dong
Keyword(s):  
Bone Resorption ◽  
Biological Activities ◽  
Bone Matrix ◽  
Osteoclast Differentiation ◽  
Bone Destruction ◽  
Bone Diseases ◽  
Therapeutic Effects ◽  
Type I ◽  
Type Iii

: Skeletal system has been considered as a highly dynamic system, in which bone-forming osteoblasts and boneresorbing osteoclasts go through continuous remodeling cycle to maintain homeostasis of bone matrix. It has been well acknowledged that interferons (IFNs), acting as a subgroup of cytokines, not only make crucial effects on regulating immunology, but also could modulate the dynamic balance of bone matrix. In the light of different isoforms, IFNs have been divided into three major categories in terms of amino acid sequences, recognition of specific receptors and biological activities. Currently, type I IFNs consist of a multi-gene family with several subtypes, of which IFN-α exerts proosteoblastogenic effects to activate osteoblast differentiation and inhibits osteoclast fusion to maintain bone matrix integrity. Meanwhile, IFN-β suppresses osteoblast-mediated bone remodeling as well as exhibits inhibitory effects on osteoclast differentiation to attenuate bone resorption. While type II IFN constitutes the only type, IFN-γ, which exerts regulatory effects on osteoclastic bone resorption and osteoblastic bone formation by biphasic ways. Interestingly, type III IFNs are regarded as new members of IFN family composed of four members, including IFN-λ1 (IL-29), IFN-λ2 (IL-28A), IFN-λ3 (IL-28B) and IFN-λ4, which have been certified to participate in bone destruction. However, the direct regulatory mechanisms underlying how type III IFNs modulate metabolic balance of bone matrix remains poorly elucidated. In this review, we have summarized functions of IFN family during physiological and pathological conditions and described the mechanisms by which IFNs maintain bone matrix homeostasis via affecting the osteoclast-osteoblast crosstalk. In addition, the potential therapeutic effects of IFNs on inflammatory bone destruction diseases such as rheumatoid arthritis (RA), osteoarthritis (OA) and infectious bone diseases are also well displayed, which are based on the predominant role of IFNs in modulating the dynamic equilibrium of bone matrix.

scholarly journals Colorectal cancer cells promote osteoclastogenesis and bone destruction through regulating EGF/ERK/CCL3 pathway

2020 ◽  
Vol 40 (6) ◽  
Author(s):  
Gong Zi-chen ◽  
Qian Jin ◽  
Zhang Yi-na ◽  
Wang Wei ◽  
Kang Xia ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Bone Marrow ◽  
Bone Metastasis ◽  
Bone Resorption ◽  
Cancer Cells ◽  
Bone Destruction ◽  
Transcriptomic Profiling ◽  
Colorectal Cancer Cells ◽  
Creb Pathway

Abstract Bone metastasis of colorectal cancer (CRC) cells leads to osteolysis. Aberrant activation of osteoclasts is responsible for bone resorption in tumor. In general, bone marrow-derived monocytes (BMMs) differentiate into osteoclasts, however, how CRC cells interact with BMMs and how to regulate the differentiation is elusive. We here report that CRC cells promote bone resorption in bone metastasis. Transcriptomic profiling revealed CCL3 up-regulated in MC-38 conditional medium treated BMMs. Further investigation demonstrated that CCL3 produced by BMMs facilitated cell infusion and thus promoted the osteoclastogenesis. In addition, CRC cells derived EGF stimulated the production of CCL3 in BMMs through activation of ERK/CREB pathway. Blockage of EGF or CCL3 can efficiently attenuate the osteolysis in bone metastasis of CRC.

scholarly journals Molecular Regulation of Bone Metastasis Pathogenesis

2018 ◽  
Vol 46 (4) ◽  
pp. 1423-1438 ◽  
Author(s):  
Meng-Yu Wu ◽  
Chia-Jung Li ◽  
Giou-Teng Yiang ◽  
Yeung-Leung Cheng ◽  
Andy Po-Yi Tsai ◽  
...  
Keyword(s):  
Bone Metastasis ◽  
Bone Metastases ◽  
Bone Fractures ◽  
Suppressor Cells ◽  
Distant Metastases ◽  
Cord Compression ◽  
Osteolytic Lesions ◽  
Parathyroid Hormone Related Protein ◽  
Osteoprotegerin Ligand

Distant metastases are the major cause of mortality in cancer patients. Bone metastases may cause bone fractures, local pain, hypercalcemia, bone marrow aplasia, and spinal cord compression. Therefore, the management of bone metastases is important in cancer treatment. Normal bone remodeling is regulated by osteoprotegerin ligand (OPGL), receptor activator of NF-κB ligand (RANKL), parathyroid hormone-related protein (PTHrP), and other cytokines. In the tumor microenvironment, tumor cells induce a vicious cycle that promotes osteoblastic and osteolytic lesions. Studies support the idea that distant metastases may occur due to the immunosuppressive function of myeloid-derived suppressor cells (MDSCs). These cells inhibit T cells and natural killer (NK) cells and differentiate into tumor-associating macrophages (TAMs), monocytes, and dendritic cells (DCs). In this review, we summarize studies focusing on the role of MDSCs in bone metastasis and provide a strong foundation for developing anticancer immune treatments and anticancer therapies, in general.

scholarly journals Towards a consensus microRNA signature of primary and metastatic colorectal cancer

2020 ◽  
Author(s):  
Bastian Fromm ◽  
Eirik Høye ◽  
Paul Heinrich Michael Böttger ◽  
Diana Domanska ◽  
Annette Torgunrud Kristensen ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Epithelial To Mesenchymal Transition ◽  
Bioinformatics Pipeline ◽  
Mesenchymal Transition ◽  
Mirna Sequencing ◽  
Bona Fide ◽  
Cell Type Specific ◽  
Metastatic Process ◽  
Metastatic Sites

AbstractBackgroundAlthough microRNAs (miRNAs) are involved in all hallmarks of cancer, miRNA dysregulation in the metastatic process remains poorly understood. We investigated the role of miRNAs in metastatic evolution of colorectal cancer (CRC) by analyzing smallRNA-seq datasets from primary CRC, metastatic locations (liver, lung and peritoneum), and corresponding adjacent tissues. Addressing main challenges of miRNA analysis, a bioinformatics pipeline was developed that contains bona fide miRNA annotations from MirGeneDB, utilizes the quality control software miRTrace, applies physiologically meaningful cutoffs and accounts for contribution of cell-type specific miRNAs and host tissue effects.ResultsTwo hundred-and-seventy-five miRNA sequencing datasets were analyzed, and after adjusting for the contribution of heterogeneity in cellular composition, strong signatures for primary and metastatic CRC were identified. The signature for primary CRC contained many previously known miRNAs with known functions. Deregulation of specific miRNAs was associated with individual metastatic sites, but the metastatic signatures contained overlapping miRNAs involved in key elements of the metastatic process, such as epithelial-to-mesenchymal transition and hypoxia. Notably, four of these miRNAs (MIR-8, MIR-10, MIR-375, MIR-210) belong to deeply conserved families present in many other organisms, triggering questions about their evolutionary functions and opportunities for experimental validation.ConclusionApplying a meticulous pipeline for the analysis of smallRNA-seq data, miRNA signatures for primary and metastatic CRC were identified, contributing novel insights into miRNA involvement in CRC metastatic evolution and site-specific metastatic adaptations. New datasets can easily be included in this publicly available pipeline to continuously improve the knowledge in the field.

Sign in / Sign up

Export Citation Format

Share Document